5 Best Genomics Stocks to Buy According to Analysts

2. Beam Therapeutics Inc. (NASDAQ:BEAM)

Analysts’ Upside Potential: 75.45%

On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. It stated the data were made on topline results from 29 patients treated as of a February 10 cutoff, with extra insights from single-dose cohorts.

Chief Medical Officer Amy Simon said the findings support treating AATD “at the root cause of disease” using a one-time gene-editing therapy. Amy noted that Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing toward pivotal development. Separately, trial investigator John Hurst said the results suggest a single dose can restore AAT function, calling the approach “a paradigm shift.”

The company said it plans to pursue quick approval following FDA feedback, expecting to enroll about 50 more patients and start a pivotal cohort in the second half of 2026.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm. It is involved in the establishment of an integrated platform for precision genetic medicines.

1281292 - 11759070 - 1